BIOMAT Database Logo BIOMAT Database Logo

A Phase I trial of talazoparib in patients with advanced hematologic malignancies. 2021

Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

OBJECTIVE The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. METHODS This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy in advanced hematologic malignancies (cohort 1: acute myeloid leukemia/myelodysplastic syndrome; cohort 2: chronic lymphocytic leukemia/mantle cell lymphoma). RESULTS Thirty-three (cohort 1: n = 25; cohort 2: n = 8) patients received talazoparib (0.1-2.0 mg once daily). The MTD was exceeded at 2.0 mg/day in cohort 1 and at 0.9 mg/day in cohort 2. Grade ≥3 adverse events were primarily hematologic. Eighteen (54.5%) patients reported stable disease. CONCLUSIONS Talazoparib is relatively well tolerated in hematologic malignancies, with a similar MTD as in solid tumors, and shows preliminary anti leukemic activity.Clinical trial registration: NCT01399840 (ClinicalTrials.gov).

UI MeSH Term Description Entries

Related Publications

Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies.
October 2012, Clinical lymphoma, myeloma & leukemia,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
Phase I trial of SU14813 in patients with advanced solid malignancies.
January 2011, Annals of oncology : official journal of the European Society for Medical Oncology,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.
July 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies.
July 1985, Cancer,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
October 2008, American journal of clinical oncology,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
March 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.
October 2017, Oncotarget,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
November 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
April 2014, American journal of hematology,
Ajay K Gopal, and Rakesh Popat, and Ryan J Mattison, and Tobias Menne, and Adrian Bloor, and Terry Gaymes, and Asim Khwaja, and Mark Juckett, and Ying Chen, and Matthew J Cotter, and Ghulam J Mufti
A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies.
January 1991, Medical and pediatric oncology,
Copied contents to your clipboard!